ANNUAL REPORT - Department of Biotechnology

F S C
# C e lls
1000
800
600
400
200
0
800
600
400
200
88.6%
0 200 400 600 800 1000
10 0
0
10 0
0
10 0
10 0
10 0
0
SSC
10 1
10 1
10 1
10 1
10 1
CD4
10 2
10 2
10 2
10 2
10 2
62%
10 3
10 3
10 3
10 3
10 3
10 4
10 4
10 4
10 4
10 4
C D 2 5
F o xP 3
10 4
10
3.69% 8.03%
4
10
3.69% 8.03%
4
10 4
10 4
10 4
3.69% 8.03%
10 3
10 3
10 3
10 3
10 3
10 3
10 2
10 2
10 2
10 2
10 2
10 2
10 1 10 1 10 1 10 1 10 1 10 1
10 0
62%
10 0
62%
10 0
10 0
10 0
10 0
62%
10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
0 1 2 3 4
10 4
10 4
10 4
10 4
10 4
10 4
10 3
10 3
10 3
10 3
10 3
10 3
10 2
10 2
10 2
10 2
10 2
10 2
10 1
10 1
10 1
10 1
10 1
10 1
0.58%
10 0 91.3%
10 0 91.3%
10 0
10 0
10 0
10 0 91.3%
CD4
26.3%
10 10 10 10 10
0 1 2 3 4
CD25
+
Presentation of Fox-3 regulatory T cells
tuberculosis patients vis-a vis healthy controls
DBT Annual Report 2006-07
2.09%
6.05%
104
Mw as an adjuvant in other clinical indications-
There are emerging indications that Mw may be
clinically useful as an immunomodulator in other
diseased indications including cancer. During the
year, the Department invited proposals to explore the
potential of Mw, both in pre-clinical and clinical
conditions and to elucidate basic pathways of the
action of Mw in appropriate animal models for cancer,
leishmania , hepatitis, rabies etc.
Dengue diagnostics and Vaccine/s
Taking into consideration the recurrent outbreaks of
dengue in the country, R&D projects have been